AZYO Aziyo Biologics

Aziyo Biologics to Participate in Upcoming Investor Conferences

Aziyo Biologics to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:

34th Annual Piper Sandler Healthcare Conference

Location: New York, NY

Format: Fireside chat and 1x1 meetings

Date: December 1, 2022

Time: 11:30 a.m. ET

Participants: C. Randall Mills, Ph.D., President and Chief Executive Officer, and Matthew Ferguson, Chief Financial Officer

Cantor Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Location: Miami, FL

Format: Panel discussion entitled “R&R: Regenerative & Restoration Medicine” and 1x1 meetings

Date: December 8, 2022

Time: 2:45 p.m. ET

Participant: C. Randal Mills, Ph.D.

A webcast of the fireside chat at the Piper Sandler conference can be accessed by visiting . A replay will be available on the Company's website following the event. A recording of the panel discussion at the Cantor conference will be made available only to clients of Cantor Fitzgerald.

About Aziyo Biologics

Aziyo Biologics is a regenerative medicine company with a commercial portfolio of differentiated products focused on improving outcomes in patients undergoing a range of surgical procedures, primarily for implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit .

Investors:

Matt Ferguson

Aziyo Biologics, Inc.

Media:

Courtney Guyer

Aziyo Biologics, Inc.



EN
21/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Regains Compliance with Nasdaq Listing Requirements GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requireme...

 PRESS RELEASE

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NX...

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's ...

 PRESS RELEASE

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, M...

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026 GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

 PRESS RELEASE

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work...

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™ GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention supp...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch